Business
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical
About this update from Iovance Biotherapeutics, Inc.
[{"type":"text","content":"86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study Initial 7 Patients Show 3 Complete Responses, 3 Partial Responses and 1 Best Response of Stable Disease ASCO Update Conference Call and Webcast on Sunday, June 6 at 12 p.m. ET SAN CARLOS, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced clinical data for lifileucel in combination with pembrolizumab in patients with advanced melanoma. The data are now available in an ePoster at the ASCO 2021 Annual Meeting. Antonio Jimeno M.D., Ph.D., Professor of Medicine/Oncology and Otolaryngology at the University of Colorado School of Medicine stated, “Anti-PD-1 therapy has become standard of care in frontline melanoma, yet we are still looking for ways to help more patients respond and to improve upon the depth and durability of responses. The 86% Overall Response Rate (ORR) for lifileucel in combination with pembrolizumab is remarkable and suggests a potential additive effect for early-line treatment of patients with melanoma. I look forward to investigating this treatment approach in additional patients with melanoma as well as in other tumor types such as head and neck squamous cancer.” Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, “We are very pleased with the initial efficacy and safety results for lifileucel in combination with pembrolizumab in patients who are naïve to anti-PD-1 therapy. We are particularly impressed by the complete response observations and noted conversion of several partial to complete responses over time. These data in melanoma also build upon our initial data for TIL in combination with pembrolizumab in head and neck cancer, supporting the broader potential for TIL in earlier anti-PD-1 naïve treatment settings across indications.” Early data suggest the response rate of lifileucel plus pembrolizumab may be additive and confirm the potential feasibility and activity of this combination in patients with immune checkpoint inhibitor (ICI)-naïve advanced melanoma. Cohort 1A in the IOV-COM-202 study is evaluating lifileucel in combination with pembrolizumab in patients who are naïve to ...